BI 1823911

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim

Drug class:

KRAS G12C inhibitor

Related drugs:

KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	BI 1823911 Sensitive: C2 – Inclusion Criteria BI 1823911 Sensitive : C2	BI 1823911 Sensitive: C2 – Inclusion Criteria BI 1823911 Sensitive : C2
KRAS G12C	Small Intestinal Carcinoma	KRAS G12C	Small Intestinal Carcinoma	BI 1823911 Sensitive: C3 – Early Trials BI 1823911 Sensitive : C3	BI 1823911 Sensitive: C3 – Early Trials BI 1823911 Sensitive : C3

Associations
(2)